LGNXZ 0.00 LIGAND PHARMACEUTICAL INC
| Range: | 0.004-0.004 | Vol Avg: | 0 | Last Div: | 0 | Changes: | 0 |
| Beta: | 0.91 | Cap: | 1.88B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Thu Jan 01 1970 | Empoloyees: | 58 | ||
| CUSIP: | 53220K181 | CIK: | 0000886163 | ISIN: | US53220K1815 | Country: | US |
| CEO: | Mr. Todd C. Davis Ph.D. | Website: | https://www.ligand.com | ||||
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow